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Ren Mao4 and Mark Martin Haenle1Abstract
Background: Ultrasonographically guided punctures of the liver represent a decisive tool in the diagnosis of many
diseases of the liver. Objective of the study was to determine the extent to which the complication rate for
ultrasonographically guided punctures of the liver is affected by less comprehensively studied risk factors.
Methods: A total of 2,229 liver biopsies were performed in 1,961 patients (55.5% males; 44.5% females). We
recorded actual complications and assessed the following risk factors: needle gauge, puncture technique, examiner
experience, coagulation status, puncture target (focal lesion versus parenchyma), lesion size, patient sex and age.
Results: he rate of complications stood at 1.2% (n = 27), of which 0.5% (n = 12) were major and 0.7% (n = 15)
minor complications. A significant increase in complications involving bleeding was observed with larger-gauge
needles compared with smaller-gauge needles and for cutting biopsy punctures compared with aspiration biopsies
(Menghini technique). In the bivariate analysis complications were 2.7 times more frequent in procedures
performed by experienced examiners compared with those with comparatively less experience. Lower values for
Quick’s test and higher partial thromboplastin times were associated with a higher rate of bleeding. Neither the
puncture target, lesion size or patient sex exerted any measurable influence on the puncture risk. Advanced patient
age was associated with a higher rate of complications involving bleeding.
Conclusions: Our study helps to establish the importance of potential and less comprehensively studied risk factors
and may contribute to further reduction in complications rates in routine clinical practice.
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Ultrasonographically guided percutaneous liver biopsies are
an important diagnostic and therapeutic option in routine
clinical practice [1-4]. They are employed in the work-up of
patients with suspected diffuse liver diseases, for treatment
monitoring and staging of hepatitis, and for diagnostic clari-
fication of hepatic lesions [1]. With their limited invasivity,
low rate of complications and brief post-procedure monitor-
ing, these interventions can usually be performed on an am-
bulatory basis, which also contributes to their cost-efficiency
[2,5,6]. The rate of minor complications is reported at 3.0-* Correspondence: wolfgang.kratzer@uniklinik-ulm.de
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reproduction in any medium, provided the or5.0%, with major complications occurring at a rate of 0.13-
5.4% [7]. The major complication most commonly reported
in the literature is bleeding [8]. The mortality rate is quite
low, ranging from 0.0% to 0.4% [2,9,10]. However, many fac-
tors may influence the risk of complications and, to date,
there is a paucity of quantitative data from studies with large
patient collectives addressing certain risk factors. A recent
published position paper by Rockey et al. [2] recognized by
the American Association for the Study of Liver Diseases
(AASLD) cites the evaluation of potential risk factors as an
important topic for future studies. The present study
addresses four of these: needle gauge, puncture technique,
examiner experience and patient’s coagulation status. In
addition, the following potential risk factors were assessed in
the present study: target of biopsy (focal lesion, paren-
chyma), lesion size, and patient’s sex and age.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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routine clinical relevance of these factors on the basis of
prospectively collected data in a large patient collective
in order to further minimize complication rates and as-
sure the greatest possible safety for patients.
Methods
Nomenclature
A biopsy was defined as an intervention in which a sin-
gle puncture target was approached through a single
puncture channel using one or more puncture needles
of the same or different diameter; one or more techni-
ques could be used. The present report gives the exter-
nal diameter of puncture needles in millimeters.
Major complications were defined as post-intervention
events that were clinically relevant and required thera-
peutic intervention (e.g. blood transfusion, drainage
etc.). Minor complications were events that were not
clinically relevant and did not require specific thera-
peutic intervention.
Patient selection
A total of 1,961 patients underwent 2,229 liver biopsies
in our institution’s department of ultrasonography dur-
ing the period of September 1999 through November
2009. In 31.5% (n = 702) of cases, liver biopsies were
performed as out-patient procedures, while in 68.5%
(n = 1527), biopsies were performed in inpatients.
The study was conducted in accordance with the prin-
ciples of the Helsinki Declaration and Good Clinical
Practice. It was approved by the ethics committee of the
State Medical Council of Baden-Württemberg (74/12).
Data collection
The following parameters were prospectively recorded:
needle diameter, puncture technique, examiner’s experi-
ence (inexperienced: < 150 liver biopsies; experience: ≥ 150
liver biopsies), patient’s coagulation status (platelet count,
Quick’s test, partial thromboplastin time [PTT]), target of
puncture (focal lesion vs. parenchyma), size of focal
lesions (size categories: < 2 cm, 2–5 cm, > 5 cm), patient’s
sex, patient’s age (age groups: < 70 years; ≥ 70 years). For
patients with complications, certain coagulation para-
meters were obtained retrospectively from the hospital’s
medical record system.
Puncture requirements
The following criteria had to be met before each punc-
ture: clear indication with therapeutic consequence; ad-
equate, current coagulation status (platelets ≥ 70,000/μl,
Quick’s test value ≥ 70%, PTT < 50 seconds) no use of
anticoagulants, and written consent signed by the pa-
tient one day prior to the procedure. In rare cases and
after careful consideration of risks and benefitspunctures were also performed in patients not meeting
the required coagulation criteria. The greatest deviations
from the routinely required coagulation parameters were
observed in patients in critical condition; they are pre-
sented in Table 1.
Execution
All punctures involving fine needle aspiration cytology
(FNAC) or cutting biopsy (CB) were performed under
ultrasonographic guidance (Philips HDI 3000/5000 Sono
CT; C5-2 curved array transducers and biopsy guid-
ance). The aspiration biopsy using the Menghini tech-
nique (ABM) was performed blind following initial
ultrasonographic monitoring of the puncture track.
The ABM was performed using a HEPAFIX Lok G 17
1.4-mm needle (B. Braun Melsungen AG, Melsungen,
Germany). The intrahepatic phase of the needle inser-
tion lasted 1–3 seconds.
For the FNAC, examiners used a puncture needle
(Chiba, diameter: 0.7 mm, length: 220 mm; Bard
Angiomed, Karlsruhe, Germany). A spinal needle (1.2 ×
90 mm; Becton Dickinson S.M., Madrid, Spain) served
as a leader canula. Following insertion of the leader
canula, puncture material was obtained by the process
of “needling”.
CB was performed in side notch technique using a
fully automated biopsy pistol (Manan Medical Products,
Inc., Wheeling, IL, USA) using Pro Mag 1.2 × 160 mm
needles (Angiotech Pharmaceuticals, Inc., Vancouver,
BC, Canada). The intrahepatic phase of both FNAC and
CB required about 5–30 seconds. When during the same
liver biopsy both a CB and FNAC were to be performed,
the FNAC was always performed first.
Patient monitoring after puncture
Following FNAC, patients were required to maintain bed
rest for four hours (three hours after CB and ABM). In
addition, they were requested to apply pressure to the
puncture site with a sandbag for one hour (for 30 minutes
after CB and ABM) and refrain from oral intake during
the same period. Blood pressure and pulse readings were
obtained every 60 minutes (every 30 minutes after CB and
ABM) and recorded. Following final complete blood
count, physical examination by the treating physician and
final ultrasonographic examination following CB and
ABM, patients were discharged. No sonographic examin-
ation was routinely performed following FNAC. Patients
with acute pain or circulatory instability following dis-
charge were advised to seek immediate medical attention
in the Emergency Department.
Statistical analysis
Statistical analysis was performed using the SAS statis-
tical software version 9.2 (SAS Institute, Inc., Cary, NC,
Table 1 Complications and required interventions in 2,229 liver biopsies
Description of complication Indication Final diagnose
Major complication (n=12)
Bleeding requiring transfusion (n=8) Potentially malignant lesion (n=6) Benigne liver tumor (n=3)
Hepatopathy (n=1) Hepatopathy (n=3)
Hepatitis (n=1) Metastases (n=2)
Vasovagal reaction (n=2) potentially malignant lesion (n=1) Metastases (n=1)
Hepatitis (n=1) Viral hepatitis (n=1)
Pneumothorax (n=1) Autoimmune disorder (n=1) No pathological findings (n=1)
Post-puncture anaphylactoid reaction (n=1) Hepatopathy (n=1) Hepatopathy (n=1)
Minor complication (n=15)
Pain, vegetative symptoms (n=3) Potentially malignant lesion (n=2) Metastases (n=2)
Hepatitis (n=1) Hepatopathy (n=1)
Large hematoma of the liver (n=1) potentially malignant lesion (n=1) Metastases (n=1)
Reduction in hemoglobin concentration without
evidence of bleeding (n=1)
Potentially malignant lesion (n=1) Chonic hepatitis (n=1)
Significant perihepatic fluid (n=1) Hepatopathy (n=1) Non-diagnostic puncture (n=1)
mild bleeding (n=9) Potentially malignant lesion (n=7) Hepatopathy (n=2)
Hepatitis (n=1) Metastases (n=4)
Hepatopathy (n=1) No pathological findings (n=2)
Poorly differentiated carcinoma (n=1)
Mueller et al. BMC Gastroenterology 2012, 12:173 Page 3 of 8
http://www.biomedcentral.com/1471-230X/12/173USA). Data was analyzed descriptively with respect to
the complication rate and bleeding rate, absolute and
relative frequency, mean, standard deviation, and max-
imum and minimum values. Potential risk factors were
assessed for correlation with complication rate and
bleeding rate using the χ2-test. If the absolute number of
complications was too small, Fisher’s Exact Test was used.
Subsequently, bivariate logistic regression was performed.
Due to the small number of cases a multivariate analysis
could not be performed. All statistical tests were two tailed.
The significance level was set at α = 5% (p < 0.05).
Results
A total of 2,229 liver biopsies were performed in 1,961
individual patients aged 18 to 96 years (mean 53.4 ±
16.1 years). 55.5% (n = 1,238) of liver biopsies were per-
formed in male patients, 44.5% (n = 991) in female
patients.
Hepatic lesions of unclear malignancy represent the
most frequent indication for liver biopsy (50.5%). Punc-
tures are also performed for therapy monitoring and
staging of hepatitis (Table 2). The most frequent post-
puncture diagnoses include diffuse liver diseases, such as
chronic hepatitis or toxic liver damage, followed by viral
hepatitis, carcinomas of hepatic origin and metastases
(Table 2).
Complication rate was 1.2% (n = 27) with major com-
plications in 0.5% (n = 12) and minor complications in
0.7% (n = 15). Bleeding rate was 0.9% (n = 20) withmajor bleeding in 0.4% (n = 8) and minor bleeding in
0.5% (n = 12). There were no puncture-related deaths.
The complications are presented in Table 1.
Overall, 39.8% (n = 1064) of the punctures were per-
formed with FNAC, 33.2% (n = 888) with CB and 26.9%
(n = 719) with ABM. The respective frequencies of the
documented techniques together with the respective
needle diameters are presented in Table 3.
Comparison of CB with FNAC
With respect to needle gauge, a significantly higher
bleeding rate of 2.7% (4/148) was reported for biopsies
of focal lesions using CB (needle diameter 1.2 mm) com-
pared with biopsies using FNAC (needle diameter
0.7 mm) with a bleeding rate of 0.0% (0/585). Biopsies of
focal lesions using both FNAC (needle diameter 0.7 mm)
and CB (needle diameter 1.2 mm) also are associated
with a bleeding rate of 2.2% (8/368) which is also higher
that that observed for biopsies at which only FNAC (nee-
dle diameter 0.7 mm) was used (Table 4). Findings of the
present study show a clear increase in bleeding complica-
tions associated with the use of thicker needles.
Comparison of CB (1.2 mm) with ABM (1.4 mm)
With respect to biopsy technique, biopsies of the hepatic
parenchyma using only CB (needle diameter 1.2 mm)
were associated with a bleeding rate of 1.8% (5/279).
This was six times higher than the bleeding rate of 0.3%
(2/717) associated with ABM (needle diameter 1.4 mm;
Table 2 Indication for liver biopsy and final diagnoses
Indication N (%)
Potentially malignant lesion 1125 (50.5%)
Hepatitis 576 (25.8%)
Transaminase elevation 76 (3.4%)
Abscess/cyst 66 (3.0%)
Hepatopathy, hepatomegaly 161 (7.2)
Lymphoma 30 (1.4)




Autoimmune disorder (autoimmune hepatitis, PBC, PSC) 87 (3.9)
Rejection reaction after liver transplantation 4 (0.2)
Jaundice of unclear origin 1 (0.04)
Thalassemia 4 (0.2)
Echinococcus infestation 3 (0.1)






Still’s disease 1 (0.04)
Alpha-1 antitrypsin deficiency 2 (0.1)
Vasculitis 1 (0.04)
Final diagnoses N (%)
Diffuse liver diseases
Viral hepatitis 336 (15.1%)
Autoimmune disorders 43 (1.9%)
Hepathopathy (NASH, ASH, steatosis, chronic hepatitis,
drug-induced liver damage, nutritional-toxic damage,
fibrosis, cirrhosis, liver necrosis, hepatosis, cholangitis,
cholestasis, Budd-Chiari Syndrome)
624 (28.0%)
Metabolic disorders 12 (0.5%)
Rejection reaction following liver transplantation 5 (0.2%)
Sarcoidosis 3 (0.1%)




Focal nodular hyperplasia 13 (0.6%)
Metastases 590 (26.5%)





Table 2 Indication for liver biopsy and final diagnoses
(Continued)
Bilioma 2 (0.1%)
Mucor mycosis 1 (0.04%)
Ethanol instillation (intervention) 12 (0.5%)
No pathological findings 307 (7.3%)
Non-diagnostic puncture 63 (2.8%)
ASH alcoholic steatohepatitis, CCC Cholangiocarcinoma, HCC Hepatocellular
carcinoma, NASH nonalcoholic steatohepatitis, PBC Primary biliary cirrhosis,
PSC Primary sclerosing cholangitis.
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[1.26-33.83], p = 0.03) (Table 4).
Examiner experience
In 60.9% (n = 1,358) of biopsies, examiners were consid-
ered “inexperienced”. A complication rate of 0.7%
(n = 10) was reported for these biopsies . By comparison,
the 39.1% (n = 871) of biopsies performed by “experi-
enced” examiners were associated with a 2.7-times
higher complication rate of 2.0% (n = 17) at bivariate re-
gression (OR = 2.68, 95% CI [1.22-5.89], p = 0.01). A
total of 45 examiners performed an average 50 ± 115
liver biopsies (range 1–756 liver biopsies). While 73.3%
(n = 33) of examiners caused no complications, the
remaining 26.7% (n = 12) experienced between one and
14 complications (Table 5).
Coagulation parameters
Coagulation parameters (platelet count, Quick’s test and
PTT) were fully documented for 34.0% (n = 757) of bi-
opsies of the liver. Coagulation parameters were docu-
mented or retrospectively ascertained in 90% (18/20) of
patients with bleeding complications. Bleeding rate for
biopsies performed in patients meeting full coagulation
criteria stood at 2.3% (16/710) compared with 4.3% (2/47)
for biopsies performed in patients not fully meeting
these criteria. This difference was not statistically sig-
nificant on bivariate logistic regression (p = 0.3911).
When the coagulation parameters were taken as con-
stant variables, however, there was a decrease in bleed-
ing rate with increasing Quick’s test values and an
increase with increasing PTT values. There was no com-
parable correlation for platelet count (Table 6).
Puncture targets
Two separate analyses were performed to assess the in-
fluence of the nature of the target lesion (focal lesions
vs. parenchyma) on bleeding rates: the first included all
biopsies of the liver, while the second focused on those
biopsies involving CB (needle diameter 1.2 mm). By ex-
cluding the factors “needle diameter” and “technique”,
exact comparability could be achieved. Neither analysis
found statistically significant differences with respect to
Table 3 Needle diameters and puncture techniques
Focal lesion n (%) Parenchyma n (%)
0.7 mm (FNAC) 1023 (38.3) 3 (0.1)
0.95 mm (FNAC) 38 (1.4) 0 (0)
1.2 mm (CB) 547 (20.5) 282 (10.6)
1.4 mm (ABM) 0 (0) 719 (26.9)
1.6 mm (CB) 48 (1.8) 11 (0.4)
ABM Aspiration biopsy (Menghini technique), CB Cutting biopsy, FNAC Fine
needle aspiration cytology.
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p = 0.30; Table 2).
Diameter of lesions
Diameter of the target lesion was documented for
1,090 biopsies. Broken down according to size, 18.0%
(n = 196) of biopsies were performed in patients with
target lesions < 2 cm in diameter with a bleeding rate
of 1.0% (n = 2); 56.2% (n = 613) with lesions 2–5 cm
in diameter with a bleeding rate of 1.3% (n = 8); and
25.8% (n = 281) with lesions > 5 cm in diameter with
a bleeding rate of 1.1% (n = 3). With respect to bleed-
ing rate, no statistically significant difference between
the three size categories could be ascertained using
Fisher’s exact test (p = 1.0).
Sex and age
Similarly, bivariate logistic regression failed to dem-
onstrate any difference for complication rate of 0.8%
(n = 10) among 1,238 biopsies in male patients vs. 1.7%
(n = 17) among 991 biopsies in female patients (p = 0.06).Table 4 Bleeding rate in relation to needle diameter, techniq
Localization Biopsies (n) Technique (Ø in mm) Major BR i
Parenchyma 1,011 All techniques 0.4 (4)
Focal lesion 1,218 All techniques 0.3 (4)
Parenchyma 717 ABM (1.4) 0.0 (0)
Parenchyma 279 CB (1.2) 0.4 (1)
Parenchyma 279 CB (1.2) 0.4 (1)
Focal lesion 148 CB (1.2) 0.0 (0)
Focal lesion 148 CB (1.2) 0.0 (0)
Focal lesion 585 FNAC (0.7) 0.0 (0)
Focal lesion 585 FNAC (0.7) 0.0 (0)
Focal lesion 368 CB & FNAC (1.2 & 0.7) 1.1 (4)
* Bivariate logistic regression, statistically significant values in bold type.
** Fisher’s exact test von Fisher, statistically significant values in bold type.
ABM Aspiration biopsy (Menghini technique), BR Bleeding rate, FNAC Fine needle asIn 82.6% of liver biopsies (n = 1842), punctures were
performed in patients < 70 years of age, with a bleeding
rate of 0.7% (n = 13). In the remaining 17.4% (n = 387) of
biopsies performed in patient ≥ 70 years of age, the bleed-
ing rate was 1.8% (n = 7) representing an increase of
2.6 times at bivariate logistic regression (OR = 2.60;
95%-CI [1.03-6.54]; p = 0.04).
Discussion
A comparison of complication rates with other studies
can be done most objectively when consideration is lim-
ited to complications involving bleeding. Our bleeding
rates of 0.4% for major bleeding and 0.5% for minor
bleeding fall toward the lower end of the ranges reported
in the literature for both major (0.0-5.3%) and minor
(0.0-5.9%) bleeding [2,7]. The rates for minor bleeding in
particular are difficult to interpret since these complica-
tions may be detected at ultrasonographic monitoring
examinations but may be otherwise clinically inapparent.
Studies suggest that minor intra- or perihepatic bleeding
detectable by ultrasound occurs in about 18-20% of liver
biopsies [2,11,12]. Ultrasonographic monitoring is, how-
ever, not routine in all centers performing liver punctu-
res. In our department, it is routine following CB and
ABM but not following FNAC. Our mortality rate of
0.0% corresponds with the very low rate of puncture-
related mortality of 0.0-0.4% documented in the litera-
ture [2,13-15].
With respect to needle gauge, our findings correspond
with data reported from two studies using anesthetized
pigs in which bleeding rate correlated with increasing
diameter of the puncture needles [16-18]. In humans, aue and localization (focal lesion, parenchyma)
n % (n) Minor BR in % (n) Total BR in % (n) p
0.3 (3) 0.7 (7) 0.3775*
0.7 (9) 1.1 (13)
0.3 (2) 0.3 (2) 0.0255*
1.4 (4) 1.8 (5)
1.4 (4) 1.8 (5) 0.5214*
3.4 (5) 3.4 (5)
3.4 (5) 3.4 (5) <0.0001**
0.0 (0) 0.0 (0)
0.0 (0) 0.0 (0) <0.0001**
1.1 (4) 2.7 (8)
piration cytology, CB Cutting biopsy.
Table 5 Rate of complications in relation to the number
of punctures performed by the respective examiners
Examiner Minor complication Major complication Total biopsies
A 1 (1.0%) 0 96
B 1 (1.6%) 0 64
C 1 (1.9%) 0 52
D 0 1 (0.6%) 156
E 0 1 (1.3%) 78
F 0 1 (1.5%) 66
G 0 1 (1.7%) 59
H 0 1 (4.2%) 24
I 0 1 (5.6%) 18
J 1 (0.6%) 1 (0.6%) 164
K 1 (1.2%) 1 (1.2%) 86
L 7 (0.9%) 7 (0.9%) 776
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spective study [19]. In that study, needles with diameters
of 1.8 mm and 1.6 mm were associated with a signifi-
cantly higher complication rate than were thinner nee-
dles 1.2 mm and 0.8 mm in diameter. Analysis of the
data, however, included findings from punctures of sev-
eral different organs; in addition, computed tomography
served as the imaging method and the overall complica-
tion rate, rather than simply assessment of bleeding
complications, was studied. This significantly limits a
direct comparison with the findings of the present study.
By contrast, two other studies failed to observe an
increased rate of bleeding complications in liver punctu-
res using larger-gauge needles [20-22]. Because of the
available data, however, these results do not appear to
justify any corresponding conclusions. In one study,
there is a lack of exact information on the number of
punctures performed with each respective needle diam-
eter [21]; in the other, the number of cases is too small
to allow valid conclusions regarding the otherwise very
low bleeding rate [20]. In fact, the currently available
data do not satisfactorily demonstrate the independence
of bleeding rate from needle diameter. On the other
hand, because of the large number of cases, clearlyTable 6 Influence of coagulation parameters on bleeding rate
Platelet
Reference range ≥ 70,000/
Findings in relation to biopsy 42.5% (n
Biopsy in patients not meeting full coagulation criteria 1.2% (n =
Most significant deviation from reference range 32,000/μl
OR [95%-CI] 1.000 [0.9
p-value * 0.8301
* Bivariate logistic regression for individual coagulation parameters considered as c
CI Confidence interval, OR Odds Ratio, PTT Partial Thromboplastin Time, s Seconds.described needle diameters and the exclusive analysis of
data obtained from biopsies of focal lesions, we consider
our findings to be very reliable and to clearly demon-
strate a significantly lower bleeding rate with the use of
thinner needles. The impact of different puncture tech-
niques (FNAC vs. CB) on these results is, in our opinion,
negligible. Both were performed in nearly identical man-
ner with respect to both the ultrasonographic guidance
of the liver biopsies and the duration of the intrahepatic
phase (5–30 seconds).
In the case of punctures of the hepatic parenchyma,
bleeding rate associated with CB (needle diameter
1.2 mm) was approximately six-times higher than that
reported for ABM (needle diameter 1.4 mm). This
correlation has not previously been adequately explained
although this had been suggested by data reported for
early retrospective studies [2,9,23,24].
An important consideration in the comparison of
these two methods is the fact that, unlike ultrasonogra-
phically guided CB, ABM is performed with ultrasono-
graphic support but not under real time conditions.
However, real-time imaging does not appear to reduce
the bleeding risk: significant bleeding usually results
from arterial sources but small arteries cannot be visua-
lized at ultrasound. By contrast, the constant ultrasono-
graphic monitoring does reduce the risk of injury to the
lung and gallbladder [2,25]. The reason for the reduced
bleeding rate with ABM, in our opinion, is the shorter
intrahepatic phase of the puncture needle (ca. 1–3 sec-
onds). Respiration-associated injuries such as tears of
the liver capsule are less likely for this reason than with
CB punctures, in which the intrahepatic phase in our in-
stitution lasts 5–30 seconds depending on puncture cir-
cumstances. This explanation has also been proposed by
Grant et al. [3]. For the indication of histological assess-
ment of cirrhosis, however, CB appears to be superior to
ABM [2,26,27].
With respect to examiner experience, a direct com-
parison between studies is difficult due to differing defi-
nitions regarding the respective examiners’ degree of
experience. Only the multi-center study reported by
Cadranel et al. [28] used the same breakdown ofs
count Quick test PTT
μl ≥ 70 % < 50 s
= 948) 43.4% (n = 968) 34.8% (n = 775)
11) 5.1% (n = 49) 1.4% (n = 11)
45% 66 s
97-1.004] 0.970 [0.0943-0.999] 1.078 [1.014-1.146]
0.0430 0.0157
onstant variables, statistically significant values in bold type.
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study, however, showed a significant reduction in com-
plication rate, both for minor complications, such as
pain and feeling unwell, and for major complications in
relation to increasing examiner experience. Other publi-
cations use different criteria for determining examiner
experience but report similar findings [18,21,29-31].
In the study by Cadranel et al., examiners with more
than 150 puncture procedures were considered experi-
enced, while those with less than 15 procedures were
considered inexperienced. No significant difference in
complication rates was reported between these two
groups [28].
In our collective, however, complication rate increase
in relation to examiner experience and do so in a statis-
tically significant manner. This unexpected observation
can be explained by the fact that difficult, “high risk” bi-
opsies are only performed by experienced examiners; the
elevated complication rate can thus be attributed to the
more difficult puncture conditions. Inexperienced exam-
iners are initially assigned patients with secure puncture
conditions and perform procedures under supervision.
In our opinion, the clear assignment of each biopsy to
the corresponding degree of examiner experience serves
to underscore our findings and could be interpreted to
indirectly support the findings of other authors that
examiner inexperience is not a risk factor for increased
complication rates [10,18,21]. This also underscores the
importance of careful supervision and a gradual ad-
vancement of less experienced examiners to increasingly
complex puncture situations. It should be noted, that
the results were exclusively calculated bivariate and
therefore other factors are not taken into account.
Our data support the conclusion of other publications
that normal or only mildly reduced coagulation
parameters do not prevent bleeding complications
[2,3,7,9,10,21,22]. Overall, 88.9% (16/18) of instances of
bleeding in the present study in patients with documen-
ted coagulation parameters occurred in patients whose
coagulation parameters were within the normal refer-
ence range. Thus, our pre-interventional coagulation
screening would not seem to have protected against
bleeding events. Reports in the literature have found
thromboplastin and PTT to be poor predictors of bleed-
ing risk in association with surgical procedures [1], how-
ever, based on our findings, we do not believe that there
is justification for dispensing with pre-interventional
screening. By comparison, Steeff et al. found a significant
correlation between the occurrence of a complication
and a platelet count < 60,000/mm3; hence, these
researchers advised against puncture biopsies in patients
with low platelet counts [8]. Patients with end-stage liver
diseases may experience more significant bleeding
[32,33]. Considering decreasing PTT and increasingthromboplastin as constant variable, we were able to as-
certain a decrease in bleeding complications. A similar
correlation for the platelet count did not emerge in the
statistical treatment of the data.
A comparison of punctures of focal lesions vs. paren-
chymal punctures failed to document an increase bleed-
ing rate. This supports data published by Frieser et al. in
the only study available to us that addresses this issue
[4]. The absence of correlation between complication
rate and lesion size confirms findings by Ch Yu et al.
[34], who, in his study of puncture-related bleeding rate
in patients with hepatocellular carcinoma (HCC), estab-
lished four size categories, finding no statistically signifi-
cant differences in terms of complication rates.
In comparison with other studies [10,28], our data did
not support any sex-specific elevation in risk. Cadranel
et al. [25] report that “pain” and “fear” assessed using a
10-point visual analog scale occurred more frequently in
female patients. In our opinion, these parameters, be-
cause of their subjectivity, do not seem useful for a gen-
der comparison. On the other hand, McGill et al. [10]
reported an increased risk of bleeding rate in relation to
the factor “sex” in combination with age, underlying ma-
lignancy and increase number of needle passes that was
found to be statistically significant at multivariate logistic
regression. Patients in our study aged 70 years and older
showed a clearly higher rate of bleeding complications
than did younger patients. An age-independent com-
plication rate, as has been reported in a large study
by Welch et al. [35], could not be confirmed by our
data. In Welch’s study, the complication rate for patients
> 80 years of age was compared with that observed
for younger patients. However, analysis of the data con-
sidered all complications, not simply bleeding: hence, a
direct comparison is difficult. When bleeding rates alone
are considered, our findings confirm data reported by
McGill et al. [29], which, on bivariate logistic regression,
showed significantly more frequent bleeding in relation
to increase patient age.
Conclusions
In conclusion, the findings of the present study show
elevated rates of bleeding when larger-caliber puncture
needles are used. A comparison of CB with ABM also
showed an increased risk for CB. A lesser degree of
examiner experience, on the other hand, did not repre-
sent a risk factor for elevated complication rates. The
coagulation parameters thromboplastin and PTT sig-
nificantly affect the bleeding rate. A similar influence
was not observed for platelet count. For the factors
puncture target (focal lesion vs. parenchyma), patient
sex and lesion side, for all of which there is a general
paucity of available data, our findings did not demon-
strate any significant differences with respect to bleeding
Mueller et al. BMC Gastroenterology 2012, 12:173 Page 8 of 8
http://www.biomedcentral.com/1471-230X/12/173rate or complication rate. Advanced age, however, was
clearly associated with an increased rate of bleeding
complications.
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